Skip to main content

Bruker Expects Q4 Revenue Jump of up to 26 Percent

NEW YORK (GenomeWeb News) - Bruker BioSciences today said it expects to report fourth-quarter revenue of between $130 million and $135 million — an increase of up to 26 percent over fourth-quarter 2005 revenues.
 
In a preliminary earnings statement issued today, Bruker said it expects full-year 2006 revenues in the range of $430 million to $435 million — growth of up to 17 percent over full-year 2005 revenues.
 
Bruker said that it has adjusted its historical financial results to account for its acquisition of Bruker Optics last July. As a result, the company reported pooled revenue of $106.8 million for the fourth quarter of 2005 and $372.3 million for the full year.
 
Bruker said it expects to report earnings of $.07 to $.09 per share for the fourth quarter.
 
Bruker said it expects "modest" improvement in income and revenue for the first quarter of 2007.
 
Bruker's CFO William Knight said the fourth quarter traditionally "has been our best quarter of the year, and our fourth quarter 2006 was particularly strong.
 
Bruker will release its full results for the fourth quarter and for the full year of 2006 on Feb. 22.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.